Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: Results of 1-year study in...
Доброволскайа О. В., Коваленко П. С., Торопцова Н. В., Дyдyкина И. С., Никитинскайа О. А., Насонов Е. Л.
Научно-практическая ревматология
Т. 57, Вып. 2, С. 160-165
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.14412/1995-4484-2019-160-165
Аннотация:
Objective: to assess bone mineral density (BMD) changes in rheumatoid arthritis (RA) patients with osteoporosis (OP) and in women with postmenopausal OP during therapy with denosumab (DSB) for 1 year Subjects and methods. 121 women were included: the main group - 69 patients with RA (mean age - 60±7 years), 34 (49.3[%]) from them received glucocorticoids (GC). Comparison group comprised 52 women with primary OP (mean age - 62±10 years). Measurement of BMD using dual-energy X-ray absorptiometry (DXA) was performed in the lumbar spine (LI-IV), femoral neck (FN), proximal femur as a whole (PF) and distal forearm (DF). DSB was administered subcutaneously at a dose of 60 mg 1 time in 6 months. Results and discussion. In patients with RA, the average increase of BMD for 12 months of treatment was: in LI-IV -4.6[%], in FN-2.8[%], in PF-3.0[%] and in DF-0.7[%], and in the comparison group - 5.2; 2.1; 2.9 and 0.9[%], respectively. There were no significant differences of BMD changes between the groups. Eff
Ключевые слова:
Bone mineral density; Denosumab; Glucocorticoid osteoporosis; Glucocorticoids; Postmenopausal osteoporosis; Rheumatoid arthritis; Secondary osteoporosis
denosumab; adult; Article; bone density; clinical practice; controlled study; drug efficacy; dual energy X ray absorptiometry; female; femoral neck; human; lumbar spine; major clinical study; postmenopause osteoporosis; proximal femur; rheumatoid arthritis
Язык текста: Русский
ISSN: 1995-4492
Доброволскайа О. В.
Коваленко П. С.
Торопцова Н. В.
Дyдyкина И. С.
Никитинскайа О. А.
Насонов Е. Л. Евгений Львович 1948-
Dobrovolskaya O. V.
Kovalenko P. S.
Toroptsova N. V.
Dydykina I. S.
Nikitinskaya O. A.
Nasonov E. L. Evgenij L`vovich 1948-
Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: Results of 1-year study in clinical practice [Сравнительная оценка эффективности деносумаба у больных ревматоидным артритом и постменопаузальным остеопорозом: результаты 1-годичного исследования в клинической практике]
Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: Results of 1-year study in...
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 57, Вып. 2 С. 160-165
2019
Статья
Bone mineral density Denosumab Glucocorticoid osteoporosis Glucocorticoids Postmenopausal osteoporosis Rheumatoid arthritis Secondary osteoporosis
denosumab adult Article bone density clinical practice controlled study drug efficacy dual energy X ray absorptiometry female femoral neck human lumbar spine major clinical study postmenopause osteoporosis proximal femur rheumatoid arthritis
Objective: to assess bone mineral density (BMD) changes in rheumatoid arthritis (RA) patients with osteoporosis (OP) and in women with postmenopausal OP during therapy with denosumab (DSB) for 1 year Subjects and methods. 121 women were included: the main group - 69 patients with RA (mean age - 60±7 years), 34 (49.3[%]) from them received glucocorticoids (GC). Comparison group comprised 52 women with primary OP (mean age - 62±10 years). Measurement of BMD using dual-energy X-ray absorptiometry (DXA) was performed in the lumbar spine (LI-IV), femoral neck (FN), proximal femur as a whole (PF) and distal forearm (DF). DSB was administered subcutaneously at a dose of 60 mg 1 time in 6 months. Results and discussion. In patients with RA, the average increase of BMD for 12 months of treatment was: in LI-IV -4.6[%], in FN-2.8[%], in PF-3.0[%] and in DF-0.7[%], and in the comparison group - 5.2; 2.1; 2.9 and 0.9[%], respectively. There were no significant differences of BMD changes between the groups. Eff